FDA Approves New Second-Line Oral Treatment For ALK+ Lung Cancer

The U.S. Food and Drug Administration has approved the oral medication Alunbrig for the treatment of ALK+ non-small cell lung cancer. Find out more about the newly approved drug treatment.